I-Juniper Biologics ibhengeze namhlanje ukuba ifumene amalungelo elayisensi yokuphuhlisa kunye nokuthengisa i-TG-C LD (i-TissueGene-C i-dose ephantsi) yonyango lwe-knee osteoarthritis.
I-600 yezigidi zeedola ze-USD zelayisensi isivumelwano esibandakanya i-Asia Pacific, uMbindi Mpuma kunye ne-Afrika yasayinwa kunye ne-Kolon Life Science kwaye kukufumana okwesibini kweJuniper Biologics kwiinyanga ezininzi. Ngaphantsi kwemiqathango yobambiswano, iJuniper Biologics iya kuba noxanduva lokuphuhlisa nokuthengisa i-TG-C LD kwiingcali zonyango kunye nezibhedlele kule mimandla. I-Kolon Life Science iya kuba noxanduva lokuxhasa uphuhliso kunye nokubonelela nge-TG-C LD.
I-TG-C LD lunyango lophando olungelulo oluye lwavunywa njengonyango lwejene lokuqala lweseli-mediated ehlabathini kwi-osteoarthritis yamadolo, [i] lolona hlobo luxhaphakileyo lwamathambo.[Ii] Ngokutsho kophando, i-osteoarthritis Kuqikelelwa ukuba ngoyena nobangela weshumi elinanye [1] okhokelayo wokukhubazeka kwihlabathi liphela kunye nezigulane eziqikelelwa kwi-300 yezigidi e-Asia Pacific nakuMbindi Mpuma kunye ne-Afrika kuphela, ehlupheka ngenxa yemiphumo ephazamisayo yesifo esidibeneyo. Yenye yeemfuno zonyango ezinkulu ezingafezekiyo phakathi kweemeko ze-musculoskeletal kunye nomngcipheko obonakaliswe ukuba wonyuka ngobudala[iii].
Unyango lokuqala lwe-cell-mediated gene gene therapy, i-TG-C LD ijolise kwi-knee osteoarthritis ngokusebenzisa inaliti enye ye-intra-articular. I-Kolon TissueGene, umnini welayisensi ye-TG-C e-United States (kungekhona i-TG-C LD), sele igqibile ulingo lwezonyango lwesigaba se-2 e-United States, kunye nedatha yokuqala ebonisa ukukhululeka kweentlungu eziqhubekayo kunye nokuphuculwa kokuhamba emva kwenaliti enye idolo elidibeneyo, ukuya kuthi ga kwiminyaka emi-2. Isigaba sesi-3 solingo lwezonyango e-United States olubandakanya izigulane ezili-1,020 lusaqhubeka ngoku ukuqinisekisa ukhuseleko nokusebenza kwe-TG-C. Ukongezelela ekuqinisekiseni ukuncitshiswa kwentlungu ephawulekayo kunye nokuphuculwa komsebenzi okubonwayo kwiSigaba se-2 solingo lwezonyango, iimvavanyo zenzelwe ukubonisa ukulibaziseka kokuqhubela phambili kwesifo ukuphumeza i-DMOAD (iSifo sokuguqula i-Osteoarthritis Drug).
I-CEO yeJuniper Biologics, uRaman Singh, uthe: "Sihlala sijonge ukuchonga iindawo esinokwenza umahluko omkhulu kuzo kwaye i-TG-C LD inikezela ngesiqabu esikhulu kwizigulana ze-knee osteoarthritis ebeziya kufuna utyando okanye ezinye iindlela zonyango. Sizibophelele ekuboneleleni ngonyango olutsha lokunyanga i-osteoarthritis yamadolo ngokuvuselelwa kwecartilage kwaye sikholelwa ukuba olu nyango lophando luza kuzisa isiqabu kwizigidi zezigulane kulo mmandla.
“Siyavuya ukusebenzisana neJuniper Biologics ukuseka iindlela ezintsha zokuba izigulana zifikelele kolu nyango lweeseli zophando. Oku kuya kuba kukuqinisekiswa kwetekhnoloji yethu kunye nexabiso layo lemarike, "utshilo uMongameli weWoosok Lee kunye ne-CEO, i-Kolon Life Science. "Sikholelwa ukuba izigulana zase-Asia Pacific, kuMbindi Mpuma kunye ne-Afrika ziya kukwazi ukuxhamla kwi-TG-C LD njengoko sihamba ngokungqongqo ekuyimiseni njengendlela yonyango esemgangathweni yehlabathi."
